Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

News Conference News ACC 2022

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Michael O'Riordan

April 06, 2022

News Conference News ACC 2022

Nitroglycerin Given Early or Late Fails to Prevent Radial Artery Occlusion: PATENS

Michael O'Riordan

March 25, 2022

News Conference News ACC 2020

More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA

Michael O'Riordan

March 28, 2020

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Caitlin E. Cox

March 18, 2017

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

Advertisement

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Nitroglycerin Given Early or Late Fails to Prevent Radial Artery Occlusion: PATENS

More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content